ReST Therapeutics

157 Church Street, 19th Floor
New Haven, CT 06510



General Information:

ReST Therapeutics is an early-stage, biotech company originally founded in 2020 in Paris, France, now located in New Haven, CT.  ReST is developing transformative therapies for patients with significant, unmet needs in Psychiatry and Neurodegeneration.

With our lead program, RST-01, we intend to disrupt the existing PTSD treatment paradigm by focusing on early intervention, immediately following a traumatic event and a patient-centric clinical development strategy. RST-01 is unique in that it selectively targets the NMDA receptors in the brain which are critical to memory consolidation. Pre-clinical testing has shown drastic reductions in fear, anxiety and depression with RST-01.

Beyond psychiatry, NMDAR selective modulation has demonstrated outstanding results in Alzheimer models, the cognitive function being integrally restored and amyloid put under control through glial cells activity, opening the door to the development of a suite of assets to restore the quality of lives of those affected by debilitating neurodegenerative diseases, particularly ALS and AD.